Cargando…
Long-term macrolides in diffuse interstitial lung diseases
In the present review we provide currently available evidence for the use of macrolides in the treatment of diffuse interstitial lung diseases (ILDs). Up to now, research on macrolides has mainly focused on three areas. First, macrolides have shown some promising results in cellular models and case...
Autores principales: | Faverio, Paola, Bini, Francesco, Vaghi, Adriano, Pesci, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488614/ https://www.ncbi.nlm.nih.gov/pubmed/29212838 http://dx.doi.org/10.1183/16000617.0082-2017 |
Ejemplares similares
-
Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy
por: Faverio, Paola, et al.
Publicado: (2018) -
Management of Chronic Respiratory Failure in Interstitial Lung Diseases: Overview and Clinical Insights
por: Faverio, Paola, et al.
Publicado: (2019) -
Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights
por: Faverio, Paola, et al.
Publicado: (2018) -
Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential
por: Sebastiani, Marco, et al.
Publicado: (2020) -
Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis
por: Dei, Giulia, et al.
Publicado: (2020)